Molecular properties prediction, anticancer and anti-inflammatory activities of some pyrimido[1,2-b]pyridazin-2-one derivatives.

Introduction: The anticancer and anti-inflammatory activities of a novel series of eleven pyrimido[1,2-b]pyridazin-2-one analogues substituted at position 7 were assessed in the current study.

Methods: The physicochemical characteristics were studied using MolSoft software. The antiproliferative activity was investigated by MTT cell viability assay, and cell cycle analysis elucidated the antiproliferative mechanism of action. Western blot analysis examined the expression levels of key pro-apoptotic (Bax, p53) and pro-survival (Bcl-2) proteins. The anti-inflammatory activity was assessed by measuring the production levels of nitric oxide in RAW264.7 cells, and the expression levels of COX-2 enzyme in LPS-activated THP-1 cells. In addition, the gene expression of various pro-inflammatory cytokines (IL-6, IL-8, IL-1β, TNF-α) and chemokines (CCL2, CXCL1, CXCL2, CXCL3) was assessed by RT-qPCR.

Results: Compound bearing a chlorine substituent displayed the highest cytotoxic activity against HCT-116 and MCF-7 cancer cells where IC values of 49.35 ± 2.685 and 69.32 ± 3.186 µM, respectively, were achieved. Compound increased the expression of pro-apoptotic proteins p53 and Bax while reducing the expression of pro-survival protein Bcl-2. Cell cycle analysis revealed that compound arrested cell cycle at the G0/G1 phase. Anti-inflammatory assessments revealed that compound displayed the strongest inhibitory activity on NO production with IC of 29.94 ± 2.24 µM, and down-regulated the expression of COX-2. Compound also induced a statistically significant decrease in the gene expression of various cytokines and chemokines.

Conclusion: These findings showed that the pyrimidine derivative displayed potent anti-inflammatory and anticancer properties , and can be selected as a lead compound for further investigation.